SRPT

Arif Bilal

Known title: Chief Tech Ops OfficerCIK: 0001959750

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Sarepta Shares New DM1 Data at Oligonucleotide Meeting. Sarepta Therapeutics presented new preclinical data for SRP-1003, a treatment for myotonic dystrophy type 1, at the 2026 Oligonucleotide Therapeutics Society Annual Meeting. The data indicated robust knockdown of pathogenic DMPK RNA in the nucleus. This update highlights the company's ongoing research efforts, while the stock currently trades near its 52-week low with a volume spike.

this person other insiders at SRPT

Transaction History

SRPT▼ Sell$52K
SRPT▲ Buy—
SRPT▼ Sell$53K
SRPT▼ Sell$884K
SRPT▲ Buy—
SRPT▼ Sell$28K
SRPT▼ Sell$24K
SRPT▼ Sell$75K
SRPT▼ Sell$636K
SRPT▼ Sell$387K
SRPT▼ Sell$906K
SRPT▼ Sell$173K
SRPT▼ Sell$49K
SRPT▼ Sell$116K
SRPT▼ Sell$37K
SRPT▲ Buy—
SRPT▼ Sell$58K
SRPT▼ Sell$61K
SRPT▼ Sell$36K
SRPT▼ Sell$30K
SRPT▼ Sell$32K
SRPT▲ Buy$0
SRPT▼ Sell$198K
SRPT▼ Sell$59K
SRPT▼ Sell$14K
SRPT▼ Sell$296K
SRPT▼ Sell$42K
SRPT▼ Sell$48K
SRPT▼ Sell$29K
SRPT▼ Sell$24K
SRPT▲ Buy$0
SRPT▼ Sell$12K
SRPT▼ Sell$25K

We use analytics to understand how market-wall is used. No personal data is sold.